$599

J&J Q2 ’19 Earnings Update

Johnson & Johnson hosted their Q2 ’19 earnings call and briefly discussed the Invokana franchise. Of note, management did not comment on the recent decision to return JNJ-64565111 rights back to Hanmi. Below, FENIX provides highlights and diabetes-related insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here